A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-Metastatic, Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 06 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Apr 2019.
- 28 Jul 2016 Status changed from not yet recruiting to recruiting.
- 20 May 2016 Planned initiation date changed from 1 May 2016 to 1 Jun 2016.